Financial reports
10-K
2023 FY
Annual report
29 Feb 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
ARS
2022 FY
Annual report to shareholders
15 Jun 23
10-Q
2023 Q1
Quarterly report
9 May 23
10-K
2022 FY
Annual report
29 Mar 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
10-Q
2022 Q1
Quarterly report
10 May 22
Current reports
8-K
Departure of Directors or Certain Officers
12 Apr 24
8-K
Departure of Directors or Certain Officers
2 Apr 24
8-K
Entry into a Material Definitive Agreement
5 Mar 24
8-K
Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
28 Feb 24
8-K
Departure of Directors or Certain Officers
8 Feb 24
8-K
Regulation FD Disclosure
4 Jan 24
8-K
Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
7 Nov 23
8-K
Regulation FD Disclosure
6 Nov 23
8-K
Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting
3 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
20 Oct 23
Registration and prospectus
S-8
Registration of securities for employees
29 Feb 24
424B5
Prospectus supplement for primary offering
17 Aug 23
S-8
Registration of securities for employees
29 Mar 23
8-A12B
Registration of securities on exchange
7 Mar 23
S-8
Registration of securities for employees
10 May 22
424B5
Prospectus supplement for primary offering
9 May 22
S-3/A
Shelf registration (amended)
9 May 22
S-3
Shelf registration
15 Mar 22
S-8
Registration of securities for employees
10 Feb 21
424B4
Prospectus supplement with pricing info
4 Feb 21
Proxies
Other
EFFECT
Notice of effectiveness
10 May 22
CORRESP
Correspondence with SEC
6 May 22
CORRESP
Correspondence with SEC
6 May 22
CORRESP
Correspondence with SEC
4 May 22
UPLOAD
Letter from SEC
22 Mar 22
EFFECT
Notice of effectiveness
4 Feb 21
CERT
Certification of approval for exchange listing
3 Feb 21
CORRESP
Correspondence with SEC
1 Feb 21
CORRESP
Correspondence with SEC
1 Feb 21
CORRESP
Correspondence with SEC
22 Jan 21
Ownership
SC 13D/A
Newtyn Management, LLC
7 Mar 24
4
der Horst Edward van
16 Feb 24
4
John Celebi
16 Feb 24
4
Erin Colgan
16 Feb 24
SC 13D/A
Newtyn Management, LLC
13 Feb 24
SC 13D
Newtyn Management, LLC
3 Nov 23
4
Stephanie Krebs
2 Nov 23
3
Stephanie Krebs
2 Nov 23
4
John Celebi
13 Sep 23
4
Patrick Stephen Gallagher
11 Sep 23